Ignite Creation Date:
2025-12-24 @ 4:55 PM
Ignite Modification Date:
2026-01-24 @ 6:30 PM
Study NCT ID:
NCT01994850
Status:
COMPLETED
Last Update Posted:
2021-01-05
First Post:
2013-11-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-11
Start Date Type:
ACTUAL
Primary Completion Date:
2017-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-01
Completion Date Type:
ACTUAL
First Submit Date:
2013-11-20
First Submit QC Date:
None
Study First Post Date:
2013-11-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-06-21
Results First Submit QC Date:
None
Results First Post Date:
2019-09-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-12-14
Last Update Post Date:
2021-01-05
Last Update Post Date Type:
ACTUAL